Cannabinoid system and regulation of feeding
DOI:
https://doi.org/10.20882/adicciones.281Keywords:
Cannabinoid system, obesity, eating disorders, feeding, metabolism.Abstract
There is increasing evidence to suggest that the cannabinoid system is a crucial mechanism in the regulation of feeding and metabolism. It is against this background that a cannabinoid antagonist, rimonabant, is about to come onto the market for the treatment of obesity. Moreover, in addition to weight-loss effect, this drug has a beneficial effect on the so-called metabolic syndrome, with changes in the lipid and glucidic metabolism not observed for other anti-obesity drugs currently available. We present a review of current knowledge in this field and data from our own studies: genetic studies of this system in eating disorders and in obesity and studies of localization of cannabinoid receptors at sites related to feeding. These studies support a state of cannabinoid hyperactivity in obesity; furthermore, such hyperactivity can constitute a prognostic factor.References
Abel, E.L. (1971). Effects of marihuana on the solution of anagrams, memory and appetite. Nature, 231, 260-261.
Abrams, D.I., Hilton, J.F., Leiser, R.J., Shade, S.B., Elbeik,
T.A. y Aweeka, F.T., et al. (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Annals of Internal Medicine, 139, 258-266.
Adami, M., Frati, P., Bertini, S., Kulkarni-Narla, A., Brown, D.R.
y de Caro, G., et al. (2002). Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. British Journal of Pharmacology, 135, 1598-1606.
Ampuero, I. (2005). Análisis molecular de los genes del sistema
endocannabinoide CNR1 y FAAH en dos condiciones psiquiátricas: alcoholismo y depresión comórbida a la enfermedad de Parkinson. Tesis doctoral. Madrid: Universidad
Complutense.
Aranceta, J., Pérez, C., Serra, L., Ribas, L., Quiles, J. y Vioque,
J., Grupo colaboreativo para el Estudio de la Obesidad en España (2003). Prevalencia de obesidad en España: resultados del estudio SEEDO 2000. Medicina Clínica, 120, 608-612.
Arias, F., Sánchez, S., Gorgojo, J.J., Almódovar, F., Fernández, S. y Llorente, F. (2006). Diferencias clínicas entre pacientes obesos mórbidos con y sin atracones. Endocrinología y Nutrición, 53, 440-447.
Arias, F., Ampuero, I., Sagredo, O., Maestro, B., Almodovar,
F. y Sánchez, S., et al. (aceptado para publicación). Lack of association between polymorphisms in cannabinoid receptor genbe (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. Psychiatric Genetics.
Arnone, M., Maruani, J., Chaperon, F., Thiebot, M.H., Poncelet, M. y Soubrie, P., et al. (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology, 132, 104–106.
Avraham, Y., Ben-Shushan, D., Breuer, A., Zolotarev, O., Okon, A. y Fink, N., et al. (2004). Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacology, Biochemistry and Behavior, 77, 675-684.
Avraham, Y., Menachem, A.B., Okun, A., Zlotarav, O., Abel,
N. y Mechoulam, R., et al. (2005). Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Research Bulletin, 65, 117-123.
Bell, C.G., Walley, A.J. y Froguel, P. (2005). The genetics of
human obesity. Nature Review Genetics, 6, 221-234.
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J.P., Le
Fur, G. y Oury-Donat, F., et al. (2003). The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology, 63, 908-914.
Berridge, K.C. (1996). Food reward: brain substrates of wanting and liking. Neuroscience and Biobehavioural Reviews, 20, 1-25.
Berthoud, H.R. (2002). Multiple neural systems controlling
food intake and body weight. Neuroscience and Biobehavioural Reviews, 26, 393-428.
Boyd, S.T. y Fremming, B.A. (2005). Rimonabant--a selective
CB1 antagonist. Annals of Pharmacotherapy, 39, 684-690.
Breivogel, C.S. y Childers, S.R. (1998). The functional neuroanatomy of brain cannabinoid receptors. Neurobiology of Diseases, 5, 417-431.
Broberger, C. (2005). Brain regulation of food intake and appetite: molecules and networks. Journal of Internal Medicine, 258, 301-327.
Budney, A.J., Hughes, J.R., Moore, B.A. y Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161, 1967-1977.
Bulik, C.M., Sullivan, P.F. y Kendler, K.S. (2003). Genetic and environmental contributions to obesity and binge eating. International Journal of Eating Disorders, 33, 293-298.
Chiang, K.P., Gerber, A.L., Sipe, J.C. y Cravatt, B.F. (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Human Molecular Genetics, 13, 2113-2119.
Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R. y Gessa, G.L. (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sciences, 63, PL113-117.
Comings, D.E., Muhleman, D., Gade, R., Johnson, P., Verde,
R. y Saucier, G., et al. (1997). Cannabinoid receptor gene (CNR1): association with i.v. drug use. Molecular Psychiatry, 2, 161-168.
Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm,
C. y Schubert, M., et al. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation, 112, 423-431.
Derbenev, A.V., Stuart, T.C. y Smith, B.N. (2004). Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. Journal of Physiology, 559, 923-938.
Despres, J.P., Golay, A. y Sjostrom, L.; Rimonabant in Obesity-Lipids Study Group. (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine, 353, 2121-2134.
Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S. y Jarai, Z., et al. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410, 822-825.
Dong, C., Li, W.D., Geller, F., Lei, L., Li, D. y Gorlova, O.Y.,
et al. (2005). Possible genomic imprinting of three human obesity-related genetic loci. American Journal of Human Genetic, 76, 427-437.
Duarte, C., Alonso, R., Bichet, N., Cohen, C., Soubrie, P. y Thiebot, M.H. (2004). Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Neuropsychopharmacology, 29, 911-920.
Engeli, S., Bohnke, J., Feldpausch, M., Gorzelniak, K., Janke, J. y Batkai, S., et al. (2005). Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 54, 2838-2843.
Foltin, R.W., Brady, J.V. y Fischman, M.W. (1986). Behavioral
analysis of marijuana effects on food intake in humans. Pharmacology, Biochemistry and Behavior, 25, 577-582.
Foltin, R.W., Fischman, M.W. y Byrne, M.F. (1988). Effects of
smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite, 11, 1-14.
Freedland, C.S., Poston, J.S. y Porrino, L.J. (2000). Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacology, Biochemistry and Behavior, 67, 265-270.
Freedland, C.S., Sharpe, A.L., Samson, H.H. y Porrino, L.J. (2001). Effects of SR141716A on ethanol and sucrose self-administration. Alcoholism, Clinical and Experimental Research, 25, 277-282.
Gardner, E.L. (2005). Endocannabinoid signaling system and
brain reward: emphasis on dopamine. Pharmacology, Biochemistry and Behavior, 81, 263-284.
Gary-Bobo, M., Elachouri, G., Scatton, B., Le Fur, G., Oury-
Donat, F. y Bensaid, M. (2006). The cannabinoid CB1
receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Molecular Pharmacology, 69, 471-478.
Gomez, R., Navarro, M., Ferrer, B., Trigo, J.M., Bilbao, A. y
Del Arco, I., et al. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience, 22, 9612-9617.
Gorgojo, J.J., Arias, F., Almódovar, F., Sánchez, S., Ramos, J.A. y Alvarez, M., et al. (2006). Sistema cannabinoide y regulación de la conducta alimentaria: II. El polimorfismo corto (AAT)n del gen del receptor cannabinoide tipo 1 (CNR1) predice una menor pérdida de peso tras tratamiento médico o quirúrgico en
pacientes con obesidad mórbida. Póster presentado al XXXIII Congreso Socidrogalcohol. Cáceres.
Greenberg, I., Kuehnle, J., Mendelson, J.H. y Bernstein, J.G. (1976). Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology, 49, 79-84.
Grice, D.E., Halmi, K.A., Fichter, M.M., Strober, M., Woodside, D.B. y Treasure, J.T., et al. (2002). Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. American Journal of Human Genetic, 70, 787-792.
Grinspoon, L. y Bakalar, J.B. (1993). Marihuana. The forbidden medicine. London: Yale University Press.
Gross, H., Ebert, M.H., Faden, V.B., Goldberg, S.C., Kaye, W.H. y Caine, E.D., et al. (1983). A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology, 3, 165-171.
Hao, S., Avraham, Y., Mechoulam, R. y Berry, E.M. (2000). Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. European Journal of Pharmacology, 392, 147-156.
Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W. y Fischman,
M.W. (1999a). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology, 141, 395-404.
Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W. y Fischman,
M.W. (1999b). Abstinence symptoms following oral THC administration to humans. Psychopharmacology, 141, 385-394.
Harrold, J.A. y Williams, G. (2006). Melanocortin-4 receptors,
beta-MSH and leptin: key elements in the satiety pathway. Peptides, 27, 365-371.
Hedley, A.A., Ogden, C.L., Johnson, C.L., Carroll, M.D., Curtin, L.R. y Flegal, K.M. (2004). Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. Journal of American Medical Association, 291, 2847-2850.
Higgs, S., Williams, C.M. y Kirkham, T.C. (2003). Cannabinoid
influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology, 165, 370-377.
Hildebrandt, A.L., Kelly-Sullivan, D.M. y Black, S.C. (2003).
Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.
European Journal of Pharmacology, 462, 125-132.
Hollister, L.E. (1971). Hunger and appetite after single doses
of marihuana, alcohol, and dextroamphetamine. Clinical Pharmacology and Therapeutics, 12, 44-49.
Hollister, L. (2001). Marijuana (cannabis) as medicine. Journal of Cannabis Therapeutics, 1, 5-28.
Horvath, T.L. (2003). Endocannabinoids and the regulation
of body fat: the smoke is clearing. Journal of Clinical Investigation, 112, 323-326.
Jamshidi, N. y Taylor, D.A. (2001). Anandamide administration
into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology, 134, 1151-1154.
Jatoi, A., Windschitl, H.E., Loprinzi, C.L., Sloan, J.A., Dakhil,
S.R. y Mailliard, J.A., et al. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology, 20, 567-573.
Jbilo, O., Ravinet-Trillou, C., Arnone, M., Buisson, I., Bribes,
E. y Peleraux, A., et al. (2005). The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal, 19, 1567-1569.
Jo, Y.H., Chen, Y.J., Chua, S.C. Jr, Talmage, D.A. y Role, L.W. (2005). Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron, 48, 1055-1066.
Kas, M.J., Van Elburg, A.A., Van Engeland, H. y Adan, R.A.
(2003). Refinement of behavioural traits in animals for the genetic dissection of eating disorders. European Journal of Pharmacology, 480, 13-20.
Kirkham, T.C., Williams, C.M., Fezza, F. y Di Marzo, V. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136, 550-557.
Kirkham, T.C. (2005). Endocannabinoids in the regulation of
appetite and body weight. Behavioral Pharmacology, 16, 297-313.
Koch, J.F. y Werner, N.A. (2000). Effects of the cannabinoid
antagonists AM 630 and AM 281 on deprivationinduced food intake in Lewis rats. Social Neuroscience Abstracts, 26, 569.
Koch , J. E . y Matthews, S.M. (2001 ) . Delt a9 tetrahydrocannabinol stimulates palatable food intake in Lewis rats: effects of peripheral and central administration. Nutritional Neuroscience, 4, 179-187.
Kola, B., Hubina, E., Tucci, S.A., Kirkham, T.C., Garcia, E.A. y
Mitchell, S.E., et al. (2005). Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry, 280, 25196-25201.
Lichtman, A.H. y Cravatt, B.F. (2005). Food for thought: endocannabinoid modulation of lipogenesis. Journal of Clinical Investigation, 115, 1130-1133.
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D. y Shugarman, L.R., et al. (2005). Meta-analysis: pharmacologic treatment of obesity. Annals of Internal Medicine, 142, 532-546.
Liu, Y.L., Connoley, I.P., Wilson, C.A. y Stock, M.J. (2005).
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep ob /Lep ob mice. International Journal of Obesity, 29, 183-187.
Loos, R.J., Katzmarzyk, P.T., Rao, D.C., Rice, T., Leon, A.S.
y Skinner, J.S., et al., HERITAGE Family Study. (2003). Genome-wide linkage scan for the metabolic syndrome in the HERITAGE Family Study. Journal of Clinical Endocrinology and Metabolism, 88, 5935-5943.
Lupica, C.R., Riegel, A.C. y Hoffman, A.F. (2004). Marijuana
and cannabinoid regulation of brain reward circuits. British Journal of Pharmacology, 143, 227-234.
Martínez-Gonzalez, D., Bonilla-Jaime, H., Morales-Otal, A.,
Henriksen, S.J., Velázquez-Moctezuma, J. y Próspero-García, O. (2004). Oleamide and anandamide effects on food intake and sexual behavior of rats. Neuroscience Letters, 364, 1-6.
Mattes, R.D., Engelman, K., Shaw, L.M. y Elsohly, M.A. (1994). Cannabinoids and appetite stimulation. Pharmacology, Biochemistry and Behaviour, 49, 187-195.
McLaughlin, P.J., Winston, K., Swezey, L., Wisniecki, A., Aberman, J. y Tardif, D.J., et al. (2003). The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behavioral Pharmacology, 14, 583-588.
Miller, C.C., Murray, T.F., Freeman, K.G. y Edwards, G.L. (2004). Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain. Physiology and Behavior, 80, 611-616.
Monteleone, P., Matias, I., Martiadis, V., De Petrocellis, L., Maj, M. y Di Marzo, V. (2005). Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology, 30, 1216-1221.
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva,
S. y Batkai, S., et al. (2005). Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation, 115, 1298-1305.
Pagotto, U. y Pasquali, R. (2005). Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet, 365, 1363-1364.
Pagotto, U. y Pasquali, R. (2006). Endocannabinoids and energy metabolism. Journal of Endocrinological Investigation, 29(Suppl), 66-76.
Pazos, R., Tolón, R.M., Benito, C., Nuñez, E., Arias, F. y Gorgojo, J.J., et al. (2006). Sistema cannabinoide y regulación de la conducta alimentaria: III. El receptor para cannabinoides CB1 y la enzima hidrolasa de ácidos grasos (FAAH) están presentes en la mucosa gástrica humana. Póster presentado a XXXIII Congreso Socidrogalcohol. Cáceres.
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J. y Rosenstock, J., RIO-North America Study Group. (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of American Medical Association, 295, 761-775.
Ramos, J.A. y Fernández, J. (2000). Uso de los cannabinoides a través de la historia. Adicciones, 12 (supl. 2), 19-30.
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N.,
Keane, P. y Maffrand, J.P., et al. (2003). Anti-obesity effect of SR141716, a CB1 receptor antagonist, in dietinduced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 284, R345-353.
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M. y
Soubrie, P. (2004). CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International Journal of Obesity and Related Metabolical Disorders, 28, 640-648.
Romero, J., Wenger, T., De Miguel, R., Ramos, J.A. yFernández-Ruiz, J.J. (1998). Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation. Life Sciences, 63, 351-356.
Rowland, N.E., Mukherjee, M. y Robertson, K. (2001). Effects
of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology, 159, 111-116.
Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F.; RIO-Diabetes Study Group. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet, 368, 1660-1672.
Schwabe, R.F. (2005). Endocannabinoids promote hepatic
lipogenesis and steatosis through CB1 receptors. Hepatology, 42, 959-961.
Siegfried, Z., Kanyas, K., Latzer, Y., Karni, O., Bloch, M. y Lerer, B., et al. (2004). Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 125, 126-130.
Simiand, J., Keane, M., Keane, P.E. y Soubrie, P. (1998). SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioral Pharmacology, 9, 179-181.
Sipe, J.C., Waalen, J., Gerber, A. y Beutler, E. (2005). Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). International Journal of Obesity, 29, 755-759.
Stellar, E. (1954). The physiology of motivation. Psychological
Reviews, 61, 5-22.
Storr, M., Gaffal, E., Saur, D., Schusdziarra, V. y Allescher, H.D. (2002). Effect of cannabinoids on neural transmission in rat gastric fundus. Canadian Journal of Physiology and Pharmacology, 80, 67-76.
Tart, C.T. (1970). Marijuana intoxication common
experiences. Nature, 226, 701-704.
Thornton-Jones, Z.D., Vickers, S.P. y Clifton, P.G. (2005).
The cannabinoid CB1 receptor antagonist SR141716A
reduces appetitive and consummatory responses for food. Psychopharmacology, 179, 452-460.
Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O. y
Rossner, S., RIO-Europe Study Group. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIOEurope study. Lancet, 365, 1389-1397.
Verty, A.N., McGregor, I.S. y Mallet, P.E. (2004). Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neuroscience Letters, 354, 217-220.
Vickers, S.P., Webster, L.J., Wyatt, A., Dourish, C.T. y Kennett,
G.A. (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology, 167, 103-111.
Volicer, L., Stelly, M., Morris, J., McLaughlin, J. y Volicer, B.J. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry, 12, 913-919.
Wadman, M. (2006). Rimonabant adds appetizing choice to
slim obesity market. Nature Medicine, 12, 27.
Ward, S.J. y Dykstra, L.A. (2005). The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behavioural Pharmacology, 16, 381-388.
Wiley, J.L., Burston, J.J., Leggett, D.C., Alekseeva, O.O., Razdan, R.K. y Mahadevan, A., et al. (2005). CB1 cannabinoid receptor-mediated modulation of food intake in mice. British Journal of Pharmacology, 145, 293-300.
Williams, C.M., Rogers, P.J. y Kirkham, T.C. (1998). Hyperphagia in pre-fed rats following oral delta9-THC. Physiology and Behavior, 65, 343-346.
Williams, C.M. y Kirkham, T.C. (1999). Anandamide induces
overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology, 143, 315-317.
Williams, C.M. y Kirkham, T.C. (2002). Observational analysis
of feeding induced by Delta9-THC and anandamide. Physiology and Behavior, 76, 241-250.
Wynne, K., Stanley, S., McGowan, B. y Bloom, S. (2005).
Appetite control. Journal of Endocrinology, 184, 291-318.
